-- ============================================================================
-- SURGERY 3 MCQ BATCH 23: Soft Tissue Tumors and Skin Lesions (Questions 1321-1380)
-- Topic: Soft Tissue Tumors, Skin Cancers, and Related Conditions
-- ============================================================================

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES

-- Benign Soft Tissue Tumors (1-12)
('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'A lipoma is:',
'A malignant tumor', 'A common benign tumor of mature adipose tissue, typically soft, mobile, and painless', 'Always requires excision', 'A vascular tumor', 'An epithelial tumor',
'B', 'Lipoma: most common soft tissue tumor. Benign, composed of mature fat cells. Typically solitary, subcutaneous, soft, lobulated, mobile, painless. Treatment: observation if asymptomatic; excision for cosmesis, symptoms, or diagnostic uncertainty. Lipomatosis: multiple lipomas. Reference: Bancroft LW. Semin Musculoskelet Radiol. 2006.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Features that suggest a lipoma may be a liposarcoma include:',
'Small size and subcutaneous location', 'Size >5cm, deep location, rapid growth, or irregular margins', 'Typical soft consistency', 'Mobile and painless', 'Superficial location only',
'B', 'Liposarcoma concerns: large size (>5cm), deep (subfascial) location, rapid growth, heterogeneous appearance on imaging, fixation, pain. Well-differentiated liposarcoma may resemble lipoma. MRI helps differentiate. Large or deep lipomas should be further investigated. Reference: Kransdorf MJ. Radiographics. 2014.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Sebaceous cyst (epidermoid cyst):',
'Contains hair follicle contents', 'Is a keratin-filled cyst lined by stratified squamous epithelium with a punctum', 'Is a true sebaceous gland cyst', 'Never gets infected', 'Is always on the scalp',
'B', 'Epidermoid cyst: often incorrectly called sebaceous cyst. Lined by stratified squamous epithelium, filled with keratin debris. Characteristic central punctum. Common on face, trunk, neck. May become infected. Treatment: complete excision including capsule to prevent recurrence. Reference: Weir CB. StatPearls. 2023.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'A dermoid cyst:',
'Is an acquired lesion', 'Is a congenital cyst containing skin appendages (hair, sebaceous glands), commonly found at fusion lines', 'Contains only keratin', 'Is always malignant', 'Is the same as epidermoid cyst',
'B', 'Dermoid cyst: congenital, contains skin appendages (hair follicles, sebaceous glands, sweat glands). Located at embryonic fusion lines (lateral eyebrow, midline). Presents in childhood. Deeper than epidermoid cysts. May have intracranial connection (nasal dermoid). Excision required. Reference: Paller AS. Hurwitz Clinical Pediatric Dermatology. 5th ed.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'A ganglion cyst:',
'Contains pus', 'Is a benign cystic lesion arising near joints or tendons, containing mucinous fluid', 'Is solid', 'Is malignant', 'Never recurs after treatment',
'B', 'Ganglion: most common soft tissue mass of hand/wrist. Benign cyst containing thick mucinous fluid, arising from joint capsule or tendon sheath. Common at dorsal wrist (scapholunate). May fluctuate in size. Treatment: observation, aspiration, or surgical excision. 20-50% recurrence. Reference: Thornburg LE. J Am Acad Orthop Surg. 1999.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Hemangioma:',
'Is a malignant vascular tumor', 'Is a benign vascular tumor that is the most common tumor of infancy, with characteristic natural history', 'Never involutes', 'Requires immediate surgery', 'Is always deep',
'B', 'Infantile hemangioma: most common tumor of infancy. Endothelial cell proliferation. Natural history: rapid proliferation (first year), followed by gradual involution (over several years). Most require observation only. Intervention for complications (vision obstruction, airway, ulceration). Propranolol is first-line medical therapy. Reference: Drolet BA. N Engl J Med. 2010.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'A neurofibroma:',
'Is always malignant', 'Is a benign nerve sheath tumor that may be solitary or multiple (neurofibromatosis)', 'Is a muscle tumor', 'Contains fat', 'Is a vascular malformation',
'B', 'Neurofibroma: benign nerve sheath tumor. Solitary: common, no syndrome association. Multiple: suggests neurofibromatosis type 1 (NF1 - von Recklinghausen disease). NF1 features: cafe-au-lait spots, axillary freckling, Lisch nodules. Plexiform neurofibromas have malignant potential. Reference: Ferner RE. Eur J Human Genet. 2007.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'A schwannoma (neurilemmoma) differs from neurofibroma in that it:',
'Is malignant', 'Is encapsulated and eccentric to the nerve, allowing enucleation', 'Is always multiple', 'Cannot be separated from nerve', 'Arises from muscle',
'B', 'Schwannoma: benign nerve sheath tumor. Key differences from neurofibroma: encapsulated, eccentric to nerve (pushes fibers aside), can be enucleated without sacrificing nerve. Neurofibroma is unencapsulated, diffusely involves nerve, requires nerve sacrifice for complete excision. Reference: Knight DM. Br J Plast Surg. 2001.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'A keloid scar:',
'Stays within wound boundaries', 'Grows beyond the original wound boundaries and rarely regresses spontaneously', 'Is the same as hypertrophic scar', 'Responds well to surgery alone', 'Is not related to genetics',
'B', 'Keloid: exuberant scar tissue extending beyond original wound margins. Does not regress. More common in dark-skinned individuals (genetic predisposition). Differ from hypertrophic scars (stay within wound, may regress). Treatment: intralesional steroids, silicone, compression, radiation after excision (50-80% recurrence with surgery alone). Reference: Berman B. J Am Acad Dermatol. 2017.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Desmoid tumors (aggressive fibromatosis):',
'Are malignant and metastasize', 'Are locally aggressive but do not metastasize, arising from musculoaponeurotic tissues', 'Are always treated surgically', 'Never recur', 'Are only in children',
'B', 'Desmoid tumor: rare fibroblastic tumor. Locally aggressive with high recurrence (25-50%), but no metastatic potential. Associated with FAP (Gardner syndrome), trauma, pregnancy. Sites: abdominal wall, mesentery, extremities. Treatment: observation (may stabilize/regress), surgery (wide margins), NSAIDs, hormonal therapy, chemotherapy. Reference: Kasper B. Ann Oncol. 2017.',
'medium', 'knowledge'),

-- Soft Tissue Sarcomas (13-25)
('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Soft tissue sarcomas are:',
'Very common tumors', 'Rare malignant tumors arising from mesenchymal tissues with many histological subtypes', 'Always superficial', 'Typically spread to lymph nodes', 'Never metastasize',
'B', 'Soft tissue sarcomas: rare malignant tumors of mesenchymal origin (1% of adult malignancies). >50 histological subtypes (liposarcoma, leiomyosarcoma, synovial sarcoma, UPS, etc.). Most common in extremities. Spread hematogenously (lungs), lymph node involvement rare. Reference: NCCN Guidelines. Soft Tissue Sarcoma. 2023.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Clinical features suspicious for soft tissue sarcoma include:',
'Small size and superficial location', 'Size >5cm, deep (subfascial) location, rapid growth, and fixation to surrounding structures', 'All painless masses', 'Lymph node enlargement', 'Only in elderly',
'B', 'Sarcoma warning signs: large (>5cm), deep to fascia, rapidly growing, firm/hard, fixed to deep structures, painful. Not specific but warrant investigation. Any soft tissue mass >5cm or deep should be imaged and biopsied. Reference: NCCN Guidelines. Soft Tissue Sarcoma. 2023.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'The initial imaging modality of choice for a suspected soft tissue sarcoma is:',
'Plain X-ray', 'MRI with contrast', 'CT scan', 'Ultrasound', 'PET scan',
'B', 'MRI: imaging of choice for soft tissue masses. Excellent soft tissue contrast, delineates tumor extent, relationship to neurovascular structures, compartment involvement. CT for pulmonary metastases (staging). PET may assess metabolic activity and response. Reference: NCCN Guidelines. Soft Tissue Sarcoma. 2023.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Biopsy of suspected soft tissue sarcoma should be:',
'Excisional for all lesions', 'Core needle biopsy or carefully planned incisional biopsy in the line of future excision', 'Fine needle aspiration', 'Avoided until surgery', 'Transverse incision preferred',
'B', 'Sarcoma biopsy principles: Core needle biopsy (preferred for most) or incisional biopsy. Planning critical: biopsy tract must be excisable with definitive surgery. Longitudinal incision in extremity, in line with muscle fibers. Avoid contaminating multiple compartments. Meticulously obtain hemostasis. Reference: Mankin HJ. J Bone Joint Surg Am. 1996.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'The primary treatment of localized soft tissue sarcoma is:',
'Chemotherapy only', 'Wide surgical excision with negative margins', 'Radiation only', 'Observation', 'Amputation always',
'B', 'Sarcoma treatment: surgery is cornerstone. Wide local excision with negative margins (≥1cm or fascial barrier). Limb-sparing surgery with adjuvant radiation preferred over amputation (equivalent outcomes). Amputation if limb-sparing not feasible or refuses radiation. Reference: NCCN Guidelines. Soft Tissue Sarcoma. 2023.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Adjuvant radiotherapy in soft tissue sarcoma:',
'Has no role', 'Reduces local recurrence when combined with surgery, especially for high-grade or close margins', 'Replaces surgery', 'Is only palliative', 'Increases metastasis',
'B', 'Adjuvant radiation: reduces local recurrence (from ~30% to <15%) after limb-sparing surgery. Indications: high grade, large tumors, close/positive margins, deep location. Can be preoperative (smaller field, lower dose, wound complications) or postoperative (higher dose, larger field, more fibrosis). Reference: Yang JC. J Clin Oncol. 1998.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'The most common site of metastasis for soft tissue sarcomas is:',
'Liver', 'Lungs', 'Bone', 'Brain', 'Lymph nodes',
'B', 'Sarcoma metastasis: hematogenous spread primarily to lungs (most common). Lymph node involvement rare (exceptions: synovial sarcoma, epithelioid sarcoma, rhabdomyosarcoma). Staging includes chest CT. Pulmonary metastasectomy may be beneficial in selected patients. Reference: NCCN Guidelines. Soft Tissue Sarcoma. 2023.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Gastrointestinal stromal tumor (GIST):',
'Is an epithelial tumor', 'Is the most common mesenchymal tumor of the GI tract, arising from interstitial cells of Cajal', 'Is always benign', 'Never responds to targeted therapy', 'Is a lymphoma',
'B', 'GIST: most common mesenchymal tumor of GI tract. Arises from interstitial cells of Cajal (pacemaker cells). Most common in stomach (60%), small bowel (30%). KIT (CD117) or PDGFRA mutations in majority. Treatment: surgery for localized; imatinib (tyrosine kinase inhibitor) revolutionized treatment of advanced GIST. Reference: Demetri GD. N Engl J Med. 2002.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Imatinib in GIST:',
'Is chemotherapy', 'Is a targeted tyrosine kinase inhibitor highly effective against KIT-positive tumors', 'Has no role in GIST', 'Is only for surgery', 'Works on all sarcomas',
'B', 'Imatinib: tyrosine kinase inhibitor targeting KIT and PDGFRA. First-line for metastatic/unresectable GIST. Response rate 50-70%. Also used as adjuvant (high-risk tumors) and neoadjuvant (borderline resectable). Resistance may develop. Second-line options: sunitinib, regorafenib. Reference: Demetri GD. N Engl J Med. 2002.',
'medium', 'knowledge'),

-- Skin Cancers (26-45)
('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'The most common type of skin cancer is:',
'Melanoma', 'Basal cell carcinoma', 'Squamous cell carcinoma', 'Merkel cell carcinoma', 'Dermatofibrosarcoma',
'B', 'Basal cell carcinoma (BCC): most common skin cancer (~80% of non-melanoma skin cancers). Slow growing, locally invasive, rarely metastasizes (<0.1%). Related to UV exposure. Most common on sun-exposed areas (face). Reference: Cameron MC. J Am Acad Dermatol. 2019.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Clinical features of basal cell carcinoma include:',
'Rapid growth and bleeding', 'Pearly, translucent papule or nodule with rolled edges, telangiectasias, and possible central ulceration', 'Pigmented lesion only', 'Lymph node involvement', 'Distant metastases',
'B', 'BCC clinical features: pearly/translucent, rolled (raised) edges, telangiectasias over surface, may have central ulceration (rodent ulcer). Subtypes: nodular (most common), superficial, morpheaform (sclerosing). Morpheaform has ill-defined borders, higher recurrence. Reference: Cameron MC. J Am Acad Dermatol. 2019.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Treatment options for basal cell carcinoma include:',
'Chemotherapy only', 'Surgical excision, Mohs micrographic surgery, curettage, radiation, or topical imiquimod', 'Observation only', 'Systemic steroids', 'Antibiotics',
'B', 'BCC treatment: Surgical excision (standard, 4mm margins for well-defined). Mohs micrographic surgery (margin control, tissue-sparing - periorbital, nose, ears). Curettage and electrodesiccation (small, nodular). Radiation (elderly, poor surgical candidates). Topical (imiquimod, 5-FU) for superficial BCC. Vismodegib for advanced. Reference: Cameron MC. J Am Acad Dermatol. 2019.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Mohs micrographic surgery is:',
'Standard excision', 'A technique for complete margin assessment with tissue conservation, ideal for high-risk skin cancers on face', 'Only for melanoma', 'Radiation therapy', 'Only for recurrent tumors',
'B', 'Mohs surgery: staged excision with immediate frozen section assessment of entire margin. Continues until margins clear. Highest cure rate (99% for primary BCC), tissue-sparing. Indications: high-risk locations (face, especially periorbital, nose, ears), aggressive histology, recurrent tumors, large lesions. Reference: Tolkachjov SN. J Am Acad Dermatol. 2017.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Squamous cell carcinoma of the skin:',
'Never metastasizes', 'Is the second most common skin cancer and has metastatic potential (2-5%)', 'Is always benign', 'Has no relation to UV exposure', 'Only occurs in non-sun-exposed areas',
'B', 'Cutaneous SCC: second most common skin cancer. Related to UV exposure, immunosuppression, chronic wounds. Metastatic potential 2-5% (higher in immunosuppressed, lip/ear, perineural invasion, large/deep tumors). Treatment: surgical excision, Mohs for high-risk. Lymph node evaluation if high-risk. Reference: Alam M. N Engl J Med. 2001.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Clinical features of squamous cell carcinoma include:',
'Pearly papule with telangiectasia', 'Scaly, crusted, or ulcerated nodule/plaque, often on sun-exposed skin', 'Pigmented mole', 'Subcutaneous nodule', 'Vesicles',
'B', 'SCC clinical features: hyperkeratotic, scaly plaque or nodule that may ulcerate. Often on sun-exposed areas (face, ears, lower lip, dorsum of hands). May arise from actinic keratosis. More aggressive behavior than BCC. Reference: Alam M. N Engl J Med. 2001.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Actinic keratosis is:',
'A benign lesion that never progresses', 'A premalignant lesion with potential to progress to squamous cell carcinoma', 'A malignant tumor', 'Unrelated to sun exposure', 'The same as seborrheic keratosis',
'B', 'Actinic keratosis: premalignant lesion of sun-damaged skin. Scaly, rough papules on sun-exposed areas. Progression to SCC: 0.1-10% per year per lesion. Treatment: cryotherapy, topical 5-FU, imiquimod, photodynamic therapy. Sun protection recommended. Reference: Cockerell CJ. J Am Acad Dermatol. 2000.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Melanoma:',
'Is the most common skin cancer', 'Is a malignant tumor of melanocytes with high metastatic potential and mortality if not caught early', 'Has excellent prognosis regardless of stage', 'Does not respond to immunotherapy', 'Only occurs in fair skin',
'B', 'Melanoma: malignant tumor of melanocytes. Most lethal skin cancer (accounts for most skin cancer deaths). Incidence increasing. Risk factors: UV exposure, fair skin, multiple nevi, family history, dysplastic nevi. Early detection (when thin) is crucial - 5-year survival for localized melanoma >99%. Reference: Swetter SM. J Am Acad Dermatol. 2019.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'The ABCDE criteria for melanoma include:',
'Age, benign, color, diameter, elevation', 'Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolution/change', 'Anatomy, bleeding, consistency, depth, extent', 'Only color and diameter', 'Only asymmetry and border',
'B', 'ABCDE criteria for melanoma: A - Asymmetry (one half different from other), B - Border irregularity (ragged, blurred, notched), C - Color variation (multiple shades of brown/black, red, white, blue), D - Diameter >6mm, E - Evolution (changing in size, shape, color). "Ugly duckling" sign also useful. Reference: Swetter SM. J Am Acad Dermatol. 2019.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'The most important prognostic factor for localized melanoma is:',
'Color', 'Breslow thickness (depth of invasion)', 'Location', 'Patient age', 'Tumor diameter',
'B', 'Breslow thickness: measured depth of invasion in mm from granular layer to deepest tumor cell. Most important prognostic factor for localized melanoma. <1mm: >95% 5-year survival. >4mm: <50% survival. Other factors: ulceration, mitotic rate, sentinel node status. Reference: Gershenwald JE. CA Cancer J Clin. 2017.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Surgical margins for melanoma are based on:',
'Patient preference', 'Breslow thickness - 1cm for ≤2mm thick, 2cm for >2mm thick', 'Fixed 3cm for all', 'Color of lesion', 'Location only',
'B', 'Melanoma excision margins based on Breslow thickness: in situ - 0.5-1cm; ≤1mm - 1cm; 1.01-2mm - 1-2cm; >2mm - 2cm. Wide local excision to fascia. Randomized trials show no benefit to margins >2cm. Reference: NCCN Guidelines. Melanoma. 2023.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Sentinel lymph node biopsy for melanoma is recommended for:',
'All melanomas', 'Intermediate thickness (≥0.8-1mm) or thinner melanomas with high-risk features', 'Melanoma in situ only', 'Metastatic melanoma', 'Only thick melanomas >4mm',
'B', 'SLNB indications in melanoma: tumors ≥0.8mm (or T1a with high-risk features like ulceration, mitoses >1/mm²). Identifies nodal metastasis for staging and guides adjuvant therapy. SLN-positive patients may benefit from completion lymph node dissection or adjuvant therapy. Reference: Wong SL. JAMA Surg. 2018.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Adjuvant therapy for high-risk melanoma includes:',
'Chemotherapy only', 'Immune checkpoint inhibitors (pembrolizumab, nivolumab) or targeted therapy (BRAF/MEK inhibitors)', 'Observation only', 'Radiation only', 'Interferon only',
'B', 'Adjuvant therapy for resected high-risk melanoma (Stage III/IV): (1) Immune checkpoint inhibitors (anti-PD-1: pembrolizumab, nivolumab), (2) BRAF/MEK inhibitors (dabrafenib/trametinib) for BRAF-mutant tumors. Improved recurrence-free survival. Interferon largely replaced. Reference: Eggermont AMM. N Engl J Med. 2018.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'BRAF mutation testing in melanoma is important because:',
'All melanomas have BRAF mutation', 'BRAF-mutant melanomas respond to targeted therapy with BRAF/MEK inhibitors', 'It determines surgical approach', 'It is diagnostic only', 'Has no therapeutic implications',
'B', 'BRAF mutation: present in ~50% of cutaneous melanomas (most commonly V600E). Targeted therapy with BRAF inhibitors (vemurafenib, dabrafenib) + MEK inhibitors (trametinib, cobimetinib) has high response rates in BRAF-mutant metastatic melanoma. All advanced melanomas should be tested. Reference: Chapman PB. N Engl J Med. 2011.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Immune checkpoint inhibitors for melanoma include:',
'Only chemotherapy agents', 'Anti-PD-1 antibodies (pembrolizumab, nivolumab) and anti-CTLA-4 (ipilimumab)', 'BRAF inhibitors only', 'Interferon only', 'Interleukin-2 only',
'B', 'Immune checkpoint inhibitors: revolutionized melanoma treatment. Anti-PD-1 (pembrolizumab, nivolumab): durable responses in 30-40%, good tolerability. Anti-CTLA-4 (ipilimumab): first checkpoint inhibitor, more toxicity. Combination increases response but more toxicity. First-line for metastatic melanoma. Reference: Wolchok JD. N Engl J Med. 2017.',
'medium', 'knowledge'),

-- Other Skin and Subcutaneous Lesions (46-60)
('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Merkel cell carcinoma is:',
'A benign tumor', 'A rare, aggressive neuroendocrine skin cancer with high rates of recurrence and metastasis', 'The most common skin cancer', 'Always cured by surgery', 'A variant of melanoma',
'B', 'Merkel cell carcinoma: rare, aggressive neuroendocrine carcinoma. Associated with UV exposure and Merkel cell polyomavirus. Typically elderly, immunocompromised. High recurrence and metastasis rates. Treatment: wide excision, SLNB, adjuvant radiation. Checkpoint inhibitors (avelumab, pembrolizumab) for advanced disease. Reference: Bichakjian CK. J Am Acad Dermatol. 2018.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Dermatofibrosarcoma protuberans (DFSP):',
'Is a common tumor', 'Is a rare, locally aggressive skin tumor with high local recurrence but rare metastasis', 'Is highly metastatic', 'Does not recur after surgery', 'Is the same as dermatofibroma',
'B', 'DFSP: rare, locally aggressive sarcoma of dermis/subcutis. Characteristically indolent but infiltrative with irregular extensions. High local recurrence (20-50%) with narrow margins. Rarely metastasizes. Treatment: wide local excision (2-3cm) or Mohs surgery. COL1A1-PDGFB fusion; imatinib effective for advanced. Reference: Llombart B. J Am Acad Dermatol. 2017.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Seborrheic keratosis:',
'Is a premalignant lesion', 'Is a common benign epithelial tumor with a "stuck-on" warty appearance', 'Requires excision always', 'Progresses to cancer', 'Is related to sun damage',
'B', 'Seborrheic keratosis: common benign epithelial tumor. Appearance: "stuck on," warty, waxy, well-demarcated, tan to dark brown. Common in elderly. No malignant potential (but may be confused with melanoma). Treatment: observation; removal if symptomatic or cosmetic concerns (curettage, cryotherapy). Reference: Hafner C. J Invest Dermatol. 2010.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Keratoacanthoma:',
'Is clearly malignant', 'Is a rapidly growing tumor that often regresses spontaneously, considered low-grade SCC or SCC variant', 'Never needs treatment', 'Is a melanoma variant', 'Grows slowly over years',
'B', 'Keratoacanthoma: rapidly growing dome-shaped nodule with central keratin plug. Characteristic history of rapid growth (weeks). Considered by many as well-differentiated SCC or SCC variant. May regress spontaneously, but often treated as SCC (excision) due to difficulty distinguishing from invasive SCC. Reference: Kwiek B. Dermatol Surg. 2016.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Bowen disease is:',
'Invasive carcinoma', 'Squamous cell carcinoma in situ, presenting as well-demarcated erythematous scaly plaque', 'A benign lesion', 'A melanoma variant', 'Always on genital area',
'B', 'Bowen disease: SCC in situ of the skin. Presents as well-demarcated, erythematous, scaly plaque. Slow growing, may progress to invasive SCC (3-5%). Risk factors: UV, arsenic, HPV. Treatment: cryotherapy, topical 5-FU/imiquimod, photodynamic therapy, excision. Reference: Morton CA. Br J Dermatol. 2014.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'A pyogenic granuloma is:',
'An infected granuloma', 'A benign vascular proliferation, often presenting as a friable, bleeding nodule', 'A malignant tumor', 'A pus-containing abscess', 'A melanoma',
'B', 'Pyogenic granuloma: misnomer - not pyogenic or true granuloma. Benign vascular proliferation (lobular capillary hemangioma). Presents as rapidly growing, friable, red nodule that bleeds easily. Common in children, pregnant women. Treatment: curettage, excision, laser. May recur. Reference: Mills SE. Sternberg''s Diagnostic Surgical Pathology. 6th ed.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Kaposi sarcoma:',
'Is a sarcoma of muscle origin', 'Is a vascular tumor associated with HHV-8, commonly seen in AIDS patients', 'Is always aggressive', 'Has no viral association', 'Is treated with antibiotics',
'B', 'Kaposi sarcoma: vascular tumor caused by HHV-8 (human herpesvirus 8). Forms: classic (elderly Mediterranean men), endemic (Africa), iatrogenic (immunosuppression), AIDS-related (most common). Purple/red macules, papules, nodules on skin, mucosa, viscera. Treatment: treat underlying condition, local therapy, chemotherapy if widespread. Reference: Cesarman E. Nat Rev Dis Primers. 2019.',
'medium', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'A pilonidal sinus is:',
'An anorectal condition', 'A chronic infection in the natal cleft containing hair, commonly affecting young hairy men', 'An arterial condition', 'A congenital cyst', 'Always in the neck',
'B', 'Pilonidal sinus: chronic infection in natal cleft. Contains hair and debris. Predominately young, hairy men. Risk factors: sitting, sweating, poor hygiene, deep natal cleft. Presents with abscess (acute) or chronic discharging sinus. Treatment: abscess drainage; chronic - excision with primary closure, open healing, or flap reconstruction. Reference: Steele SR. Dis Colon Rectum. 2013.',
'easy', 'knowledge'),

('c0000038-0000-0000-0000-000000000038', 'a0000003-0000-0000-0000-000000000003',
'Hidradenitis suppurativa:',
'Is a single abscess', 'Is a chronic inflammatory condition affecting apocrine gland-bearing skin with recurrent abscesses and sinus tracts', 'Is easily cured with antibiotics', 'Only affects men', 'Is the same as acne',
'B', 'Hidradenitis suppurativa: chronic, recurrent inflammatory disease of apocrine gland regions (axillae, groin, perineum). Features: painful nodules, abscesses, sinus tracts, scarring. Risk factors: smoking, obesity, genetics. Treatment: weight loss, smoking cessation, antibiotics, biologics (adalimumab), surgery for severe cases. Reference: Zouboulis CC. Lancet. 2017.',
'medium', 'knowledge');

SELECT 'Surgery 3 MCQ Batch 23 (Soft Tissue Tumors): 60 questions inserted' as status;
